Please login to the form below

Is the world ready for a COVID-19 vaccine?

At the beginning of November, Pfizer and BioNTech announced that their vaccine candidate was more than 90% effective at preventing COVID-19 infection. Since then, other good news has followed, with collaborations, including Moderna and AstraZeneca, publishing similarly positive results. This is a phenomenal feat that would have been unimaginable just one year ago. But a vaccine is only as effective as its deployment and uptake. There should be no doubt that as soon as the first COVID-19 vaccine was approved, a very difficult logistics game ensued. The reality is that a COVID-19 vaccine will present a whole new unfamiliar set of operational challenges. There are currently more than 170 candidate vaccines in development, each with its own benefits and each with its own challenges. Here, we explore some of those challenges and reflect on what must be considered by health systems and governments to set us on track towards pandemic recovery.

By Shannon Lacombe, Hanover Health

At the beginning of the coronavirus pandemic, Dr Tedros Adhanom Ghebreyesus, Director General of the World Health Organization (WHO), dramatically told a G20 Leaders’ Summit that “we are at war with a virus that threatens to tear us apart.” At the same meeting, António Guterres, UN General Secretary, said “we are at war with a virus – and not winning it... this war needs a war-time plan to fight it”.

While there has been contention and debate about the appropriateness of the wartime analogy, it does seem to work to describe the unprecedented scale and effort required to sequester and defeat this virus. And while not military strategists, we can speculate that any “war-time plan” should be made up of a number of parts and that its success is reliant on the sum of those parts. In this case, a significant component is the successful development and roll out of a COVID-19 vaccine.

At the beginning of November, Pfizer and BioNTech announced that their vaccine candidate was more than 90% effective at preventing COVID-19 infection, based on initial results from their ongoing Phase 3 clinical trial. While the roll out of this vaccine still requires approvals by many national regulatory agencies, at the time of writing, both the UK and Canada had moved ahead with authorizations of the vaccine. Furthermore, the companies stated they could have as many as 50 million doses produced by the end of 2020 and 1.3 billion doses by the end of 2021. Since this initial announcement, other good news in vaccine development has followed, with companies and collaborations, including Moderna and the AstraZeneca/University of Oxford team, publishing similarly positive trial results.

This is a phenomenal feat and one which would have been largely unimaginable just one year ago. Vaccines pass through multiple stages of development and in normal times, it wouldn’t be unusual for the process to take 10–15 years. In COVID-19 times, this process has taken less than 12 months.

It is one of the greatest breakthroughs in modern medicine to have developed a vaccine in this timescale. But a vaccine is only as effective as its deployment and uptake. There should be no doubt that as soon as the first COVID-19 vaccine was approved, a very difficult logistics game ensued. The reality is that a COVID-19 vaccine will present a whole new unfamiliar set of operational challenges.

In the situation where the vaccine gets to everyone who would benefit from it, millions of doses will need to travel hundreds, if not thousands, of miles from manufacturers to hospitals, to general practices and pharmacies, which in turn must store, track and eventually administer the vaccines. This isn’t completely new territory; organisations such as the Centers for Disease Control and Prevention (CDC) in the United States, which distributed flu vaccines during the 2009 H1N1 pandemic with the help of local organisations, manage the roll out of routine immunisations every day.

A few of the coronavirus vaccines being trialled use “messenger” RNA (mRNA) technology. While this novel vaccine technology has never received approval before, it looks like it may be one of a few optimal and innovative immunisation approaches. After injection into muscle, the synthetic mRNA is taken up by cells and the cell’s machinery reads it to make a surface protein of the SARS-CoV-2 virus, called the “spike protein”. The rest of the process is identical to that used by other vaccines, where the immune system mounts a response by recognising the viral protein as foreign and develops antibodies against it.

One of the reasons these vaccines have progressed so quickly to, and through, clinical trials is because they are the fastest to make and manufacture. Within weeks, clinical batches can be generated through a process that is cell-free and scalable. However, on the flip side, these vaccines may also be the slowest or most difficult to deploy. While they rely on a technology whose central advantage hinges on rapidity of manufacture, its downfall is extreme physical fragility.

These first mRNA vaccines must be frozen at extremely low temperatures, and once thawed, will stay intact for only a short period of time. Furthermore, these vaccines must be given in two separate doses, administered weeks apart and both doses must come from the same manufacturer. This means that vaccine administration will require careful record tracing and tracking, which may be less of a challenge in a single-payer health system, but poses a whole set of challenges for countries and states that do not have immunisation registries or ways of tracking patients. In time, some of these challenges may be overcome, for example, if the technology used for mRNA vaccines advances to allow them to be stored at higher temperatures. However, the novelty of these vaccines means that even the manufacturers are still figuring out these challenges.

Another, and perhaps grander, challenge is one of global vaccine equity and reducing inequalities in access. One of the ways the world is looking to mitigate this is through the COVAX initiative, which is co-led by the Coalition for Epidemic Preparedness Innovations (CEPI), the Global Alliance for Vaccines and Immunisation (GAVI) and the WHO. COVAX is a multinational collaborative platform that is supporting the research, development and manufacturing of a wide range of COVID-19 vaccine candidates. All participating countries, regardless of income levels, will have equal access to these vaccines once they are developed. The initial aim is to have 2 billion doses available by the end of 2021, which should be enough to protect high-risk and vulnerable people, as well as frontline healthcare workers. Without the successful implementation of COVAX, there is a very real risk that the majority of people in the world would go unprotected against COVID-19 and the pandemic would continue to wreak havoc.

To have a truly effective prevention approach, first we need COVID-19 vaccines that are both safe and effective; we then need these to be manufactured at scale; and finally, we need them to be deployed effectively and to all corners of the world. Of course, another key piece of an effective vaccination roll-out is being able to communicate to the public about all of these aspects of a complicated topic.

The above is not an exhaustive list but should illustrate that this is not going to be a straightforward exercise. While a lot of the messaging around ending the pandemic has been reliant on the success of a vaccine, this does not mean that once a vaccine has arrived, the pandemic is over. There are still a lot of kinks to work out and a lot of challenges to overcome. The development of an effective vaccine remains truly a phenomenal feat, but it is only step one, and the healthcare industry would be doing the world a disservice if it did not acknowledge that.

It is also critical to understand that a vaccine is not the only piece to the pandemic puzzle. Whilst it remains one of the components (albeit a key one), there are other key components, including effective therapeutics and lifestyle interventions – all of which will play their part in our success.

There are currently more than 170 candidate vaccines in development, each with its own benefits and each with its own challenges. Where one vaccine may be more stable and easier to store, another may be more effective in older people, and another may require fewer doses. We are on the cusp of modern medicine’s most impressive influx of innovation and the first wave of vaccines are certainly not going to be the only important ones.

To end with the contentious war-time analogy – we may be well on our way to winning this battle, but we are still fighting a war. All of us—across industry, advocacy organisations and policymakers—have some more time ahead of us in the trenches before we can claim ourselves victorious.

As companies continue to publish positive results from vaccine trials, it will be critical for the pharmaceutical sector, advocacy organisations, and decision makers, to consider how to ensure all of those that will benefit most urgently from a vaccine, receive it. As healthcare policy specialists, we must work to support organisations and stakeholders during this time to navigate a complex and evolving landscape.

To further explore how we can support companies and advocacy partners during this complex time, please contact us.

18th December 2020


Company Details

Hanover Communications

+44 (0)20 7400 4480

Contact Website

Riverside House
Southwark Bridge House
United Kingdom

Latest content on this profile

Femtech: Transforming the future of women's healthcare
Femtech is potentially the most important development in health care right now. Women's health has been under-researched and overlooked for successive generations - it's time that government and industry get ready to deliver.
Hanover Communications
VPAS: The importance of making the right arguments, even in challenging times
With key workers’ strikes, inflation, and immense pressure on public services, arguing for a more generous pricing settlement for the pharmaceuticals industry could not be tougher. Read our Health Director James Mole’s thoughts on the support needed to protect the UK life sciences’ ambitions, despite the challenging backdrop.
Hanover Communications
Putting prevention at the heart of the future of the NHS
Prioritising the prevention of cardiovascular disease (CVD) should be at the heart of plans to safeguard the long-term sustainability of the NHS. Unfortunately, action in this area has to date not matched ambition, putting thousands of patients’ lives – and the future of the health system – at risk.
Hanover Communications
Action on Anti-microbial resistance: Will the UK rise to the challenge
Timely and effective antimicrobials are the cornerstone of our healthcare systems, providing life-saving treatment and supporting vital services like routine operations, transplants and cancer treatment. We are three years into the UK Government’s 20-Year Vision for Antimicrobial Resistance (AMR), and the Department of Health and Social Care recently launched a consultation for the next iteration of the AMR National Action Plan (2024-2029). However, latest figures show that AMR is still on the rise. Is UK policy ambitious enough to drive innovation in AMR, and is the Government on track to contain, control and mitigate AMR by 2040?
Hanover Communications
Winter and workforce woes: challenges facing the new Secretary of State for Health and Social Care
For the third time this year, the NHS and social care has a new Secretary of State. The appointment must now signal stability following a period of political turbulence, as we head into what health leaders are describing as the toughest winter to date. Backlogs, delayed discharges, ambulance and A&E pressures, and crumbling NHS estates will remain top of Steve Barclay’s priority list in the coming weeks and months ahead. However, he will also need to address the longstanding workforce issues that hold back both the NHS and social care sector. Only dealing with these structural challenges will ensure the health and care system is operationally fit for winters to come.
Hanover Communications
A new 10-year cancer plan: Will the government be able to deliver what the sector needs?
The Truss Government has committ­ed to developing a new 10-year cancer plan. But set against the backdrop of the Secretary of States priorities, what real value can the sector expect a new cancer plan to deliver? What questions need addressing to drive impactful change for patients? Will there be funding available to support the transformation?  We will explore the state of play of cancer care in England and assess the main priorities, including how they align with wider NHS challenges. We will set out the difficult choices that a new plan must confront to enable prioritisation of this complex disease area and consider the balance between taking action to impact patients now versus initiatives to benefit patients of the future.
Hanover Communications